Instrument Inactif

Communiqués APTINYX

Actions

APTX

US03836N1037

Communiqués

11/05/23	APTINYX INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
05/05/23	APTINYX INC. : Other Events, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
25/04/23	APTINYX INC. : Termination of a Material Definitive Agreement (form 8-K)	AQ
18/04/23	APTINYX INC. : Change in Directors or Principal Officers (form 8-K)	AQ
30/03/23	APTINYX INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
30/03/23	Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives	BU
30/03/23	Henry Gosebruch, Former AbbVie EVP and Chief Strategy Officer, Joins ACELYRIN, INC. Board of Directors	AQ
01/03/23	Aptinyx : Costs Associated with Exit/Disposal - Form 8-K	PU
01/03/23	APTINYX INC. : Costs Associated with Exit or Disposal Activities (form 8-K)	AQ
27/02/23	APTINYX INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
27/02/23	Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update	BU
31/01/23	Aptinyx to Present at the SVB Securities Global Biopharma Conference	BU
08/12/22	APTINYX INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
01/12/22	APTINYX INC. : Change in Directors or Principal Officers (form 8-K)	AQ
10/11/22	Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience	BU
08/11/22	APTINYX INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
08/11/22	Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights	BU
03/11/22	Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant	BU
18/10/22	Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022	BU
25/08/22	APTINYX INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
25/08/22	Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies	BU
12/08/22	Aptinyx : Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia - Form 8-K	PU
12/08/22	APTINYX INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/08/22	Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia	BU
04/08/22	Aptinyx : Reports Second Quarter 2022 Financial Results and Recent Highlights - Form 8-K	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Communiqués APTINYX

Actions

APTX

US03836N1037

Communiqués

Filtres